Inflammatory markers in adults with prader-willi syndrome before and during 12 months growth hormone treatment

Hormone Research

Volumn 66, Issue 1, 2006, Pages 27-32

  Höybye, Charlotte ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adults; GH treatment; Inflammatory markers; Prader Willi syndrome

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; GROWTH HORMONE; INSULIN; INTERLEUKIN 6; LEPTIN; SOMATOMEDIN C; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGE; ANTHROPOMETRY; ARTICLE; BODY COMPOSITION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CORRELATION FUNCTION; CYTOKINE RELEASE; FEMALE; FOLLOW UP; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; MALE; METABOLIC PARAMETERS; PRADER WILLI SYNDROME; PRIORITY JOURNAL;

ADIPONECTIN; ADOLESCENT; ADULT; ANTHROPOMETRY; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY COMPOSITION; C-REACTIVE PROTEIN; CHOLESTEROL; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INFLAMMATION; INSULIN; INSULIN-LIKE GROWTH FACTOR I; INTERLEUKIN-6; LEPTIN; MALE; OBESITY; PRADER-WILLI SYNDROME; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33745434271     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093229     Document Type: Article

References (30)

1. Hak AE, Stehouwer CD, Bots ML, Polderman KH, Schalwijk CG, Westendorp IC, Hofman A, Witteman JC: Association of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler Thromb Vasc Biol 1999;19:1986-1991.
2. Visser M, Bouter LM, McQuillian GM, Wener MH, Harris TB: Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282:2131-2135.
3. McLaghlin T, Abbasi F, Lamendola C, Liang L, Reaven G, Schaaf P, Reaven P: Differentiation between obesity and insulin resistance in the association with C-reactive protein. Circulation 2002;106:2908-2912.
4. Blake GJ, Ridker PM: Inflammatory biomarkers and cardiovascular risk prediction. J Intern Med 2002;252:283-294.
5. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-334.
6. Hotammisligil GS: The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med 1999;245:621-625.
7. Pai JK, Piscon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB: Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 2004;351; 25:2599-2610.
8. Burman P, Ritzén EM, Lindgren AC: Endocrine dysfunction in Prader Willi syndrome: a review with special reference to GH. Endocr Rev 2001;22:787-799.
9. Höybye C: Endocrine and metabolic aspects of Prader Willi syndrome with special emphasis on the effect of growth hormone treatment. Growth Horm IGF Res 2003;14:1-15.
10. WhittingtonJE, Holland AJ, Webb T, Butler J, Clarke D, Boer H: Population prevalence and estimated birth incidence and mortality rate for people wih Prader-Willi syndrome in one UK Health Region. J Genet 2001;38:792-798.
11. Schrander-Stumpel CT, Curfs LM, Sastrowijoto P, Cassidy SB, Schrander JJ, Fryns JP: Prader-Willi syndrome: causes of death in an international series of 27 cases. Am J Med Genet A 2004;124:333-338.
12. Vogels A, Van Den Ende J, Keymolen K, Mortier G, Devriendt K, Legius E, Fryns JP: Minimum prevalence, birth incidence and cause of death for Prader-Willi syndrome in Flanders. Eur J Hum Genet 2004;12:238-240.
13. Verhelst J, Abs R: Long-term growth hormone replacement therapy in hypopituitary adults. Drugs 2002;62:2399-2412.
14. Monson JP: Long-term experience with GH replacement therapy: efficacy and safety. Eur J Endocrinol 2003;148:S9-S14.
15. Rosén T, Edén S, Larsson G, Wilhelmsen L, Bengtsson BA: Cardiovascular risk factors in adult patients with growth hormone deficiency. Acta Endocrinol (Copenh) 1993;129:195-200.
16. Bulow B, Hagmar L, Mikoczy Z, Nordström CH, Erfurth EM: Increased cardiovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 1997;46:75-81.
17. Marzullo P, Marcassa C, Campini R, Eleuteri E, Minocci A, Priano L, Temporelli P, Sartorio A, Vettor R, Luizzi A, Grugni G: The impact of GH/IGF-I axis and nocturnal breathing disorders on cardiovascular features of adult patients with Prader-Willi Syndrome. J Clin Endocrinol Metab 2005;10:5639-5646.
18. Bang P, Wiwall IL, Eriksson U, Sara V, Hall K: Comparison of acid ethanol extraction and acid gel filtration prior to IGF-1 and IGF-2 radioimmunoassay: Improvement of determination in acid ethanol extracts by the use of truncated IGF-1 as radioligand. Acta Endocrinol (Copenh) 1991;107:563-570.
19. Hilding A, Hall K, Wivall-Helleryd IL, Sääf M, Melin AL, Thorén M: Serum levels of insulin-like growth factor 1 in 152 patients with growth hormone deficiency, aged 19-82 years, in relation to those in healthy subjects. J Clin Endocrinol Metab 1999;84:2013-2019.
20. Höybye C, Bruun JM, Richelsen B, Flyvbjerg A, Frystyk J: Serum adiponectin levels in adults with Prader-Willi syndrome are independent of anthropometrical parameters and do not change with GH treatment. Eur J Endocrinol 2004;15:157-161.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and M-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.
22. Albareda M, Rodrigues-Espinosa J, Murugo M, de Leiva A, Corcoy R: Assesment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test. Diabetologia 2000;43:1507-1511.
23. Bonora E, Kiechl S, Willeit J, Willet J, Obenhollenzer F, Egger G, Targher G, Alberiche M, Bonadonna RC, Muggeo M: Prevalence of insulin resistance in metabolic disorders. The Bruneck Study. Diabetes 1998;47:1643-1649.
24. Wajchenberg BL: Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000;21:697-738.
25. Goldstone AP, Thomas EL, Brynes AE, Bell JD, Frost G, Saeed N, Hajnal JV, Howard JK, Holland A, Bloom SR: Visceral adipose tissue and metabolic complications of obesity are reduced in Prader-Willi syndrome female adults: evidence for novel influences on body fat distribution. J Clin Endocrinol Metab 2001;86:4330-4338.
26. Höybye C, Hilding A, Jacobsson H, Thorén M: Metabolic profile and body composition in adults with Prader-Willi syndrome and severe obesity. J Clin Endocrinol Metab 2002;87:3590-3597.
27. Sesmilo G, Biller BM, Llevadot J: Effects of growth hormone administration on inflammatory and other cardiovaskular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med 2000;133:111-122.
28. Sesmilo G, Miller KK, Hayden D, Klibanski A: Inflammatory cardiovascular risk markers in women with hypopituitarism. J Clin Endocrinol Metab 2001;86:5774-5781.
29. Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM: Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001;357:425-431.
30. Greenswag LR: Adults with Prader-Willi syndrome. A survey of 232 cases. Dev Med Child Neurol 1987;29:145-152.